FDA OKs Tecentriq for Extensive-Stage Small Cell Lung Cancer
TUESDAY, March 19, 2019 -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer.
The drug has been approved as a first-line treatment for the disease to be used in combination with the chemotherapy drugs carboplatin and etoposide.
Tecentriq was evaluated in a clinical study involving 403 adults who had received no prior chemotherapy, the FDA said in a news release. Average survival for those who took the Tecentriq combination was 12.3 months compared with 10.3 months among those who took the chemotherapy drugs and a placebo.
The most common side effects among the Tecentriq group were fatigue, nausea, alopecia, constipation, and loss of appetite.
The newly approved drug is produced by Genentech, based in South San Francisco.
© 2020 HealthDay. All rights reserved.
Posted: March 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.